Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$1.50 USD
-0.06 (-3.85%)
Updated Apr 22, 2024 11:55 AM ET
After-Market: $1.58 +0.08 (5.33%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CUE 1.50 -0.06(-3.85%)
Will CUE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CUE
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
CUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
Other News for CUE
Biotech Alert: Searches spiking for these stocks today
Cue Energy Secures New Gas Supply Deal
Central Petroleum Expands NT Gas Supply
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning